The National Comprehensive Cancer Network (NCCN) guideline recommends broad molecular profiling, including screening for the presence of activating alterations in EGFR, ALK, ROS1, BRAF, KRAS, MET, ERBB2, and RET to inform the selection of effective targeted therapies for NSCLC patients. Here, ERBB2 is linked to non-small cell lung carcinoma.